Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Investors unloaded shares of this Irish biotech following a setback from the FDA.

Why Amarin Stock Dropped 19% in August

Biotech stocks tend to react badly to advisory committee meetings.

Amarin: Keep Your Dry Powder Ready

Clinical Practice Guidelines address how best to prevent cardiovascular events in high-risk patients with elevated triglycerides on statin treatment, among millions of people globally Clinical Practice Guidelines address how best to prevent cardiovascular events in high-risk patients with elevated triglycerides on statin treatment, among millions of people globally

New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Management of Dyslipidaemias Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes Study

The Vascepa recommendation as the standards of care by both the American Diabetes Association and American Heart Association is a stellar development that foretells robust growth ahead.

Amarin: Elucidating Bullish And Bearish Claims

BEDMINSTER, N.J. and DUBLIN, Ireland, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019, from 8:45-9:10 a.m. Eastern Time in New York City. A live audio webcast of the presentation will be available at:  http://www.amarincorp.com , and will be accessible at the same link for 30 days.

Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference

BEDMINSTER, N.J. and DUBLIN, Ireland, Aug.  27, 2019  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today provided an update on the growing interest in information on Amarin’s REDUCE-IT™ study and the potential for use of Vascepa ® (icosapent ethyl) in studied patients at risk for a cardiovascular event. Cardiovascular disease (CVD) is worldwide the #1 killer of men and women.1,2 REDUCE-IT studied the effects of Vascepa on the reduction of major adverse cardiovascular events in a high-risk patient population. The study results are currently under regulatory review in the United States and Canada.

Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management

New studies have been published clearly differentiating between Vascepa and various fish oil and dietary supplements.

An Important New Study That Bolsters Amarin's Value Proposition For Vascepa

Amarin's shares have tanked from its $23.90 peak to as low as $14 and this is a good opportunity to buy call options post November 14.

Trade On Amarin Weakness

Intuitive Surgical

Teladoc

These three health care stocks deserve your undivided attention right now.

3 Top Healthcare Stocks; to Buy Right Now

BEDMINSTER, N.J. and DUBLIN, Ireland, Aug.  21, 2019  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to participate in a fireside chat regarding Amarin at Citi’s 14th Annual Biotech Conference on Wednesday, September 4, 2019, from 2:15-2:55 p.m. Eastern Time in Boston. A live audio webcast of the presentation will be available at:  http://www.amarincorp.com , and will be accessible at the same link for 30 days.

Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference

GW Pharmaceuticals

Two mid-cap biotechs. Two tremendously successful drugs already on the market.

Better Buy: GW Pharmaceuticals vs. Amarin

The FDA announced that it is planning on holding an Adcom on November 14 to discuss the sNDA for Vascepa's expanded label.

Amarin: A Surprise AdCom For Vascepa

Amarin Corp just received notice from the FDA that they have planned an Advisory Committee for Vascepa on November 14th, which is almost two months after the company's current PDUFA.

Amarin: FDA Throws Last Minute AdCom For Vascepa

The FDA will hold an advisory committee meeting after all.

Why Amarin Stock Is Tanking Today

Shares of the mid-cap biotech Amarin Corporation plc (NASDAQ: AMRN) were pulling back to their lowest level since early January on Friday.

Amarin Shares Topple On Adcom Meeting Surprise For Fish Oil Pill

Amarin Corp. PLC (NASDAQ: AMRN) shares dropped on Friday after the firm announced that it received notice from the U.S.

Is Amarin’s Cardio Trial in Trouble?

AMRN has had two negative news recently, and these have managed to drop the stock 20%.

Amarin: A Spate Of Negative News That Ultimately Does Not Matter

Heron Therapeutics

The biotechnology industry is an exciting one. A mix of technology and a better understanding of the human body has led to several very exciting breakthroughs over the past several years, and we’re seeing improved quality of life, less abrasive therapies and longer lifespans among patients than ever before.

Biotech Stocks to Watch Through the 2nd Half of 2019

Amarin Corporation PLC (AMRN) CEO John Thero on Q2 2019 Results - Earnings Call Transcript

The drugmaker's revenue soared in Q2 driven by continued momentum for triglyceride-lowering drug Vascepa.

What You'll Want to Know About Amarin's Strong Q2 Results

The biopharma is gearing up for Vascepa's highly-anticipated label expansion.

3 Takeaways From Amarin's Earnings

Amarin beats estimates for both earnings and revenues in the second quarter of 2019. Shares up.

Amarin (AMRN) Beats Earnings & Beats Revenues in Q2

Don't be caught off-guard: Amarin Corp (NASDAQ: AMRN) releases its next round of earnings this Wednesday, July 31.

A Preview Of Amarin's Q2 Earnings

Amarin's Recent Negative News And Why It Doesn't Matter

Amarin Corp. recently executed a $400M offering at $18.00 per share that should provide Vascepa with sufficient funding for expanded commercial activities.

News for Amarin Corporation Plc Stock (AMRN)